Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wesana Health Holdings Inc. (WSNAF)
Chicago, IL, US
Wesana Health Holdings Inc. is a life sciences firm dedicated to advancing and providing psychedelic-based therapies, including psilocybin-enhanced psychotherapy, primarily targeting the treatment of traumatic brain injuries (TBI). The company focuses on pioneering scientifically validated compounds and therapeutic strategies. Its mission is to enable patients suffering from trauma-related neurological, psychological, and mental health conditions to achieve recovery. Wesana Health is headquartered in Chicago, Illinois.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +16.43% | +63.00% | -34.80% | -62.09% | -99.26% | -99.26% | -99.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+79.1% ★ Q3'24: -105.6% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'24: +33.0% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+1.9% ★ Q3'24: +0.0% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.13× Q3'24: -1.89× (vs Q3'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
30.2K
est: 278.0K (-89.1%)
|
267.2K
est: 278.0K (-3.9%)
|
—
est: 200.0K (-100.0%)
|
—
|
278.0K
278.0K – 278.0K
|
200.0K
200.0K – 200.0K
-28.1% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-87.2K
est: 55.6K (-256.8%)
|
-6.21M
est: 55.6K (-11,277.3%)
|
-2.87M
est: 40.0K (-7,279.7%)
|
-1.89M
|
55.6K
55.6K – 55.6K
|
40.0K
40.0K – 40.0K
-28.1% YoY
|
—
— – —
-100.0% YoY
|
| EBIT |
—
est: 55.6K (-100.0%)
|
-6.27M
est: 55.6K (-11,373.2%)
|
-2.97M
est: 40.0K (-7,522.0%)
|
-2.06M
|
55.6K
55.6K – 55.6K
|
40.0K
40.0K – 40.0K
-28.1% YoY
|
—
— – —
-100.0% YoY
|
| Net Income |
-87.2K
est: -31.19M (+99.7%)
|
-34.34M
est: -31.19M (-10.1%)
|
-8.60M
est: -10.51M (+18.2%)
|
-1.75M
est: -7.01M (+75.0%)
|
-31.19M
-31.19M – -31.19M
-345.0% YoY
|
-10.51M
-10.51M – -10.51M
+66.3% YoY
|
-7.01M
-7.01M – -7.01M
+33.3% YoY
|
| SGA |
72.3K
est: 2.51M (-97.1%)
|
10.62M
est: 2.51M (+323.2%)
|
3.06M
est: 1.81M (+69.7%)
|
1.12M
|
2.51M
2.51M – 2.51M
|
1.81M
1.81M – 1.81M
-28.1% YoY
|
—
— – —
-100.0% YoY
|
| EPS |
-0.01
est: -0.89 (+99.2%)
|
-1.47
est: -0.89 (-65.2%)
|
-0.24
est: -0.30 (+20.0%)
|
-0.05
est: -0.20 (+75.0%)
|
-0.89
-0.89 – -0.89
-345.0% YoY
|
-0.30
-0.30 – -0.30
+66.3% YoY
|
-0.20
-0.20 – -0.20
+33.3% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Carcillo | Co-Founder, Chief Executive Officer & Chairman | 444.2K | male |
| Mark A. Wingertzahn | Chief Scientific Officer | 402.3K | — |
| Zed Wang | Corporate Secretary | 207.5K | male |
| Chad Bronstein | Co-Founder | 126.3K | male |
| Jeffrey T. Jewell | Senior Vice President of Medical & Scientific Affairs | — | male |
| Izzy Forman | Vice President of Communications | — | — |
| Keenan Gentry | Vice President of Investor Relations & Corporate Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WSNAF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
